SALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology, announces a new articulation of the startup’s unique and patented technology through the medical device company’s website: https://nu-medplus.com/

Nu-Med Plus engineers and builds the next generation of nitric oxide delivery systems. Nitric oxide is not nitrous oxide. Rather, nitric oxide is a naturally occurring molecule with life-saving properties. The healing power of nitric oxide is currently utilized in neonatal care, cardiology, and adult respiratory issues.

Jeff Robins CEO of Nu-Med Plus remarked, “The patented and patent-pending technology Nu-Med Plus is building to safely deliver nitric oxide is being purpose-built to disrupt current markets and open new markets. Those markets in the treatment of malaria, COPD, tuberculosis, ARDS and wound healing present billions of dollars in annual value and more importantly present the potential to save and better millions of lives.” 

Nu-Med Plus Inc.’s current pipeline includes four products. The units utilize patent-pending technology and include a hospital unit designed for patients on ventilators, a clinical unit for emergency rooms, nursing homes and clinics, and a lightweight and portable unit for rapid response anywhere in the world. Each of these units are available commercially upon FDA approval. Nu-Med Plus recently developed the Nu-Med Plus 100 (NMP 100), the world’s first nitric oxide dilution system purpose-built for research. The unit is already being utilized in academic research.               

Robins continued, “The nitric oxide delivery landscape is changing, and our innovative approach, proven technology, and more precise engineering is targeted at exceptional growth potential. Explore our new online presence to see how we’re changing the future of nitric oxide delivery.”

Follow the latest news from Nu-Med Plus on Twitter at @NuMedPlus and on LinkedIn.

Media Contact: eric@s2spr.com

About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011, is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy focuses on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com. Follow Nu-Med Plus on Twitter and LinkedIn for the latest news.

Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.